Efalizumab. Plaque psoriasis: Too many unknowns

Prescrire International

Volumn 15, Issue 81, 2006, Pages 8-11

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTIBIOTIC AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; LIVE VACCINE; LIVER ENZYME; METHOTREXATE; PLACEBO; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABSCESS; ABSENCE OF SIDE EFFECTS; ANGIONEUROTIC EDEMA; ARTICLE; ASEPTIC MENINGITIS; BACTEREMIA; CHILL; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHRODERMA; FLU LIKE SYNDROME; FRANCE; HEADACHE; HEARING IMPAIRMENT; HEMOLYTIC ANEMIA; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; LEGIONNAIRE DISEASE; LEUKOCYTOSIS; LIVER DYSFUNCTION; LYMPHOMA; MYELITIS; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONHUMAN; OSTEOMYELITIS; PATIENT SATISFACTION; PHOTOTHERAPY; PNEUMONIA; PREGNANCY; PSORIASIS VULGARIS; PUVA; RELAPSE; SEPTICEMIA; SINUSITIS; SKIN CANCER; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS; URTICARIA; COMPARATIVE STUDY; ECONOMICS; PSORIASIS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DRUG COSTS; HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS; TREATMENT OUTCOME;

EID: 31844434991     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. European Medicines Agency - CHMP "European Public Assessment report (Rev. 1) - Raptiva. Scientific discussion", 22 December 2004: 37 pages.
2. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: STN/BLA 125075/0 Medical review(s)" 27 October 2003: 165 pages.
3. Commission des Communautés européennes "RCP - Raptiva" 8 September 2005: 13 pages.
4. Leonardi CL et al. "Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial" J Am Acad Dermatol 2005; 52 (3 part 1): 425-433.
5. Lebwohl M et al. "A novel targeted T-cell modulator, efalizumab, for plaque psoriasis" N Engl J Med 2003; 349 (21): 2004-2013.
6. Gordon KB et al. "Efalizumab for patients with moderate to severe plaque psoriasis" JAMA 2003; 290 (23): 3073-3080 + correction JAMA 2004; 291 (9): 1070.
7. Menter A et al. "Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis" Arch Dermatol 2005; 141 (1): 31-38.
8. Genentech "Important drug warning regarding Raptivao (efalizumab)" 15 July 2005: 2 pages.
9. Finlay AY and Khan GK "Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use" Clin Exp Dermatol 1994, 19: 210-216.